Rhone Poulenc Report issue

Contributed to NME For profit Phase 1 Phase 4
Founded: Lyon France (1928)
Status: Acquired by Rhone-Poulenc Rorer (1990) → now Sanofi-Aventis (2004)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1953
ethopropazine (parsidol)
First NDA Approval
1953
ethopropazine (parsidol)
Last Known Activity
1996

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (9)

alimemazine (temaril) (1968 NDA)

calcitonin salmon (Calcimar) (1975 NDA)

docetaxel (taxotere) (1996 NDA)

ethopropazine (parsidol) (1953 NDA)

methaqualone (NDA)

perindopril (aceon) (NDA)

pyrazinamide (Aldinamide) (NDA)

riluzole (rilutek) (1995 NDA)

tramadol (Ultram) (NDA)

Drugs in Phase 4 Trials (1)

Key: Rhone Poulenc (0) Acquired (1)

procaine benzylpenicillin (novocaine) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Rhone Poulenc (0) Acquired (1)

garlic (2 trials)

Drugs in Other Trials (12)

Key: Rhone Poulenc (0) Acquired (12)

bifidobacterium lactis (1 trial)

c6 ketone di-ester (2 trials)

erythritol (1 trial)

fiber (1 trial)

gingerol (1 trial)

ketone monoester (1 trial)

maltodextrin (1 trial)

sc-fos (1 trial)

thiethylperazine (torecan) (1 trial)

thiocarb (2 trials)

totum-63 (1 trial)

turmeric (1 trial)

Overview

  • Highest Phase: None
  • # of Trials: 15
  • # of Trial APIs: 14